Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

1.

Proliferative retinopathy in Duchenne muscular dystrophy and its response to bevacizumab.

Fagan XJ, Levy J, Al-Qureshi S, Harper CA.

Clin Experiment Ophthalmol. 2012 Dec;40(9):906-7. doi: 10.1111/j.1442-9071.2012.02822.x. No abstract available.

PMID:
22594924
[PubMed - indexed for MEDLINE]
2.

Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy.

Ernst BJ, García-Aguirre G, Oliver SC, Olson JL, Mandava N, Quiroz-Mercado H.

Acta Ophthalmol. 2012 Nov;90(7):e573-4. doi: 10.1111/j.1755-3768.2011.02364.x. Epub 2012 Mar 9. No abstract available.

PMID:
22405048
[PubMed - indexed for MEDLINE]
3.

Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2.

Ozkaya A, Alkin Z, Karakucuk Y, Yazici AT, Demirok A.

Middle East Afr J Ophthalmol. 2013 Oct-Dec;20(4):360-2. doi: 10.4103/0974-9233.120005.

PMID:
24339691
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy.

Yamaji H, Shiraga F, Shiragami C, Nomoto H, Fujita T, Fukuda K.

Arch Ophthalmol. 2011 Jan;129(1):106-7. doi: 10.1001/archophthalmol.2010.333. No abstract available.

PMID:
21220639
[PubMed - indexed for MEDLINE]
5.

Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia.

Roller AB, Folk JC, Patel NM, Boldt HC, Russell SR, Abramoff MD, Mahajan VB.

Retina. 2011 Oct;31(9):1848-55. doi: 10.1097/IAE.0b013e31820d3feb.

PMID:
21610563
[PubMed - indexed for MEDLINE]
6.

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A.

Ophthalmology. 2006 Oct;113(10):1695.e1-15.

PMID:
17011951
[PubMed - indexed for MEDLINE]
7.

Exudative retinal astrocytic hamartoma diagnosed and treated with pars plana vitrectomy and intravitreal bevacizumab.

Nakayama M, Keino H, Hirakata A, Okada AA, Terado Y.

Eye (Lond). 2012 Sep;26(9):1272-3. doi: 10.1038/eye.2012.124. Epub 2012 Jun 22. No abstract available.

PMID:
22722490
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2.

Narayanan R, Chhablani J, Sinha M, Dave V, Tyagi M, Pappuru RR, Kuppermann BD.

Retina. 2012 Nov-Dec;32(10):2001-5. doi: 10.1097/IAE.0b013e3182625c1d.

PMID:
22990322
[PubMed - indexed for MEDLINE]
9.

What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?

Spandau U.

Acta Ophthalmol. 2013 Mar;91(2):e154. doi: 10.1111/j.1755-3768.2012.02552.x. Epub 2012 Sep 19. No abstract available.

PMID:
22989079
[PubMed - indexed for MEDLINE]
10.

Regression of rubeosis in the fellow eye after intravitreal ranibizumab injection.

Lüke J, Nassar K, Grisanti S, Lüke M.

Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):371-3. doi: 10.1007/s00417-012-2184-4. Epub 2012 Nov 7. No abstract available.

PMID:
23132337
[PubMed - indexed for MEDLINE]
11.

Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia.

Moon BG, Kim YJ, Yoon YH, Lee JY.

Graefes Arch Clin Exp Ophthalmol. 2012 Nov;250(11):1697-9. doi: 10.1007/s00417-011-1798-2. Epub 2011 Aug 24. No abstract available.

PMID:
21863255
[PubMed - indexed for MEDLINE]
12.

Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.

Soliman W, Lund-Andersen H, Larsen M.

Acta Ophthalmol Scand. 2006 Oct;84(5):707-8. No abstract available.

PMID:
16965507
[PubMed - indexed for MEDLINE]
13.

Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.

Spandau UH, Jonas JB.

Acta Ophthalmol Scand. 2007 May;85(3):340-1. No abstract available.

PMID:
17488467
[PubMed - indexed for MEDLINE]
14.

Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.

Schmidinger G, Maar N, Bolz M, Scholda C, Schmidt-Erfurth U.

Acta Ophthalmol. 2011 Feb;89(1):76-81. doi: 10.1111/j.1755-3768.2009.01622.x.

PMID:
21272288
[PubMed - indexed for MEDLINE]
15.

Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.

Hufendiek K, Hufendiek K, Panagakis G, Helbig H, Gamulescu MA.

Int Ophthalmol. 2012 Jun;32(3):259-68. doi: 10.1007/s10792-012-9562-0. Epub 2012 Apr 18.

PMID:
22527448
[PubMed - indexed for MEDLINE]
16.

Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.

Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R.

Acta Ophthalmol Scand. 2006 Dec;84(6):834-5. No abstract available.

PMID:
17083555
[PubMed - indexed for MEDLINE]
17.

Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.

Tatlipinar S, Dinç UA, Yenerel NM, Görgün E.

Clin Exp Optom. 2012 Jan;95(1):94-8. doi: 10.1111/j.1444-0938.2011.00662.x. Epub 2011 Sep 28.

PMID:
21954975
[PubMed - indexed for MEDLINE]
18.

Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia.

Rishi P, Rishi E, Shroff D.

Indian J Ophthalmol. 2009 May-Jun;57(3):241-2. doi: 10.4103/0301-4738.49406. No abstract available.

PMID:
19384026
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series.

Abdelhakim MA, Macky TA, Mansour KA, Mortada HA.

Ophthalmic Res. 2011;45(1):23-30. doi: 10.1159/000314721. Epub 2010 Aug 11.

PMID:
20714187
[PubMed - indexed for MEDLINE]
20.

Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization.

Stergiou PK, Symeonidis C, Dimitrakos SA.

Acta Ophthalmol. 2011 May;89(3):218-21. doi: 10.1111/j.1755-3768.2009.01669.x.

PMID:
19860769
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk